SIU Academy® - Official eLearning Portal of SIU (Société Internationale d'Urologie)

Randomized Trial of Narrow-band Versus White-light Cystoscopy for Restaging (Second-look) Transurethral Resection of Bladder Tumors
Speaker(s):
Stephen Williams
,
Stephen Williams
Affiliations:
Ashish M. Kamat
Ashish M. Kamat
Affiliations:
SIU Academy®. Presenters F. 10/03/14; 63585 Topic: Research
Stephen Williams
Ashish M. Kamat
Login now to access Regular content available to all registered users.

To have an exclusive access to the entire content available on SIU Academy, become an SIU Member here.

You may also access SIU content "anytime, anywhere" with the FREE SIU ACADEMY App for iOS and Android.
Editorial Review
{$tab-review-references}
Discussion Forum (0)
Rate & Comment (0)
This single-surgeon, randomized, controlled trial examined patients who underwent narrow-band imaging (NBI) versus white-light imaging (WLI) during transurethral resection (TUR) for bladder tumours. Patients with high-risk (high-grade pTa, pT1, carcinoma in situ [CIS]) bladder neoplasms were evaluated. All patients underwent restaging TUR after first WLI-TUR and were randomized 1:1 by random permuted blocks to undergo either WLI-assisted or NBI-assisted second TUR. Patients underwent an induction course of bacillus Calmette-Guérin (BCG) therapy and received no maintenance therapy. Of the 254 patients, 127 underwent NBI-TUR and 127 had WLI-TUR; 22% of the patients in the NBI-TUR group recurred compared with 33% after WLI-TUR (p=0.05). The mean recurrence-free survival (RFS) time was significantly greater for the NBI-TUR group at 22 months versus 19 months for the WLI-TUR group (p=0.02). As mentioned by the author, limitations include the study being underpowered and observer bias due to NBI-TUR being performed after both WLI and NBI cystoscopy were used to inspect the bladder.
While the study is thought provoking, a multiinstitutional randomized study needs to be conducted in a larger number of patients prior to concluding definitive superiority as well as cost effectiveness of NBI-TUR for bladder tumours. Moreover, utilization of induction followed by maintenance BCG therapy in such a trial would be of interest.
References 1. Eur Urol. 2014 Jul 17. pii: S0302-2838(14)00623-X. doi: 10.1016/j.eururo.2014.06.049. [Epub ahead of print]
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies